Cargando…
Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome
OBJECTIVES: Benzodiazepines (BZDs) are the first-line drugs in alcohol-withdrawal syndrome (AWS). Baclofen, a gamma-aminobutyric acid(B) (GABA(B)) agonist, controls withdrawal symptoms without causing significant adverse effects. The objective of this study was to compare the cost-effectiveness of b...
Autores principales: | Reddy, Vikram K., Girish, K., Lakshmi, Pandit, Vijendra, R., Kumar, Ajay, Harsha, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118528/ https://www.ncbi.nlm.nih.gov/pubmed/25097273 http://dx.doi.org/10.4103/0253-7613.135947 |
Ejemplares similares
-
A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome
por: Girish, K., et al.
Publicado: (2016) -
Cost-effectiveness of the baclofen versus chlordiazepoxide in alcohol withdrawal syndrome
por: Tin, Sim Sai, et al.
Publicado: (2015) -
Chlordiazepoxide-induced delirium in a patient undergoing alcohol withdrawal: a case report
por: Arabadjief, Melissa A., et al.
Publicado: (2022) -
Baclofen and the Alcohol Withdrawal Syndrome-A Short Review
por: Cooney, Gary, et al.
Publicado: (2019) -
Continuous Intravenous Flumazenil Infusion Used in Iatrogenic Chlordiazepoxide Overdose in the Setting of Alcoholic Withdrawal Syndrome Management
por: Volney, Giselle S, et al.
Publicado: (2020)